EUVIMEDEUVIMED entdecken
Crossref

No Survival Advantage of Intermediate Radiotherapy Dose Escalation in Stage III NSCLC Receiving Delayed Immunotherapy after Chemoradiation

Jinwoo Park, Minji Kim, Seung Lee

Asian Journal of Current Research in Clinical Cancer · 2026 · 6 (1) · 59-75

DOI: 10.51847/1d1hozjkgn ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Journal of Current Research in Clinical Cancer, 2026. Verfasst von Jinwoo Park und 2 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Park, J., Kim, M., & Lee, S. (2026). No Survival Advantage of Intermediate Radiotherapy Dose Escalation in Stage III NSCLC Receiving Delayed Immunotherapy after Chemoradiation. Asian Journal of Current Research in Clinical Cancer, 6(1), 59-75. https://doi.org/10.51847/1d1hozjkgn

Vancouver

Park J, Kim M, Lee S. No Survival Advantage of Intermediate Radiotherapy Dose Escalation in Stage III NSCLC Receiving Delayed Immunotherapy after Chemoradiation. Asian Journal of Current Research in Clinical Cancer. 2026;6(1):59-75. doi:10.51847/1d1hozjkgn

BibTeX
@article{Park2026,
  author = {Park, Jinwoo and Kim, Minji and Lee, Seung},
  title = {No Survival Advantage of Intermediate Radiotherapy Dose Escalation in Stage III NSCLC Receiving Delayed Immunotherapy after Chemoradiation},
  journal = {Asian Journal of Current Research in Clinical Cancer},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {59--75},
  doi = {10.51847/1d1hozjkgn}
}
Kostenlos starten →